Key result
The highest quartile of lipid accumulation product was independently associated with increased risks of arterial stiffness (OR 1.88; 95% CI 1.37-2.58), chronic kidney disease, and micro-albuminuria.
Why the study?
Lipid accumulation product is a novel index correlating with cardiovascular disease, but its relationship with target organ damage in elderly individuals required investigation.
Is higher lipid accumulation product associated with an increased risk of target organ damage in elderly community-dwelling individuals?
Cross-Sectional (n=3,363)
Is higher lipid accumulation product associated with an increased risk of target organ damage in elderly community-dwelling individuals?
Odds Ratio: 1.88 (95% CI 1.37–2.58)
p-value: p=< 0.001
Lipid accumulation product is a novel metabolic parameter independently associated with arterial stiffness, micro-albuminuria, and chronic kidney disease in elderly Chinese individuals.
LAP may flag higher TOD risk in elderly; leaves open added value beyond standard markers.
Introduction: Lipid accumulation product (LAP), calculated from waist circumference (WC) and triglycerides (TG), is a novel index that correlates cardiovascular disease. We aimed to investigate the relationship between LAP and target organ damage (TOD) in elderly Chinese community-dwelling individuals. Materials and Methods: We enrolled 3363 participants whose age was ≥ 65 years old. TOD, including left ventricular hypertrophy (LVH), arterial stiffness (AS), lower extremity atherosclerotic (LEA), micro-albuminuria (MAU) and chronic kidney disease (CKD), was measured using standard methods. LAP was calculated as (WC– 65) × TG in men and (WC– 58) × TG in women. Both quartiles and continuation of LAP were analyzed. Results: Age-sex adjusted partial correlation analysis showed that LAP was significantly associated with CVD risk factors. With the first quartile (Q1) as a reference, in univariate logistic regression, the fourth quartile (Q4) of LAP was associated with all TOD. In multivariate model, Q4 of LAP was only associated with an increased risk of AS (odds ratio (OR) = 1.88, 95% confidence interval (CI): 1.37– 2.58, P for trend < 0.001), MAU (OR = 1.33, 95% CI: 1.01– 1.75, P for trend = 0.02) and CKD (OR = 2.39, 95% CI: 1.39– 4.12, P for trend < 0.001). But, Q4 of LAP was not associated with an increased risk of LVH (OR = 1.19, 95% CI: 0.85– 1.65, P for trend = 0.25) or LEA (OR = 0.87, 95% CI: 0.58– 1.29, P for trend = 0.96). Similar associations were found when analyzed continuously. Conclusion: The novel metabolic parameter LAP is significantly and independently associated with an increased risk of arterial stiffness, chronic kidney disease and micro-albuminuria in Chinese community-dwelling elderly individuals.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2021) conducted a cross-sectional in Target organ damage (n=3,363). Lipid accumulation product (LAP) vs. First quartile (Q1) of LAP was evaluated on Arterial stiffness (OR 1.88, 95% CI 1.37-2.58, p=< 0.001). The highest quartile of lipid accumulation product was independently associated with increased risks of arterial stiffness (OR 1.88; 95% CI 1.37-2.58), chronic kidney disease, and micro-albuminuria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: